Hospitals seen facing limited impact from anti-cancer drug price cap
In short
Goldman Sachs said the anti-cancer drug price cap is likely to have only a limited effect on hospital chains. The report says talks with hospitals and industry participants suggest most multi-specialty hospital chains will not see a big earnings hit.
This matters because hospital and pharma stocks are in focus. The report does not say the exact price cap or which drugs are covered.
What the reporting says
Goldman Sachs said the expected impact on hospital chains from an anti-cancer drug price cap is likely to be limited, according to a CNBC TV18 summary. The report says discussions with hospitals and industry participants suggest most multi-specialty hospital chains are unlikely to see a significant earnings hit. The immediate consequence for hospital and pharma stocks is a market focus on the rule, while the exact cap and scope are not stated in the available reporting.
Why it matters
Goldman Sachs said the anti-cancer drug price cap is expected to have a limited effect on hospital chains, based on discussions with hospitals and industry participants. The summary says most multi-specialty hospital chains are unlikely to face a significant earnings impact. That should reduce fears of a large hit to hospital stocks, but the reporting does not identify the cap level or the policy scope.